Amid growing delays and rising costs in U.S. clinical trials, biotechs are looking for smarter ways to accelerate development. Yooni Kim, Managing Director - Asia Pacific at Novotech, emphasizes the value of an ex-U.S. strategy that balances speed, cost, and data quality.
“It’s too late to just look at the United States. We need to quickly administer [the drug] to patients, obtain data, and check whether it is a ‘good drug or not,’” says Kim. She points to Australia’s streamlined approval timelines and generous R&D tax rebate as one example of a region delivering decisive early data while maintaining quality.
“For early-stage companies, time is the most important asset,” Kim explains. “Initial human data obtained quickly has a decisive impact on development speed and strategic decisions.” From early-phase trials in Australia to patient recruitment in Southeast Asia and complex designs in Korea, Novotech guides sponsors to choose the right regions at each stage.
As Kim notes, “The CRO is not just an organization that acts on behalf of the clinical trial, but a partner who understands the strategic goals of the sponsor and designs the action plan together.”
Explore how Novotech’s deep Asia-Pacific network and global capabilities help biotech sponsors navigate bottlenecks and bring life-changing therapies to market faster.
Read the full article here (Korean Language): [link]